Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Basel, June 7, 2022 — Novartis today announced longer-term follow-up data from the Phase III ASCEMBL trial for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors (TKIs), presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. In this analysis, the proportion of patients in the Scemblix® (asciminib) arm (n=157) who achieved a major molecular response (MMR) at 96 weeks was more than double that in the Bosulif® (bosutinib) arm (n=76) (37.6% vs. 15.8% [P=.001]), substantially increasing from previous analyses1,2. Additionally, the probability of maintaining MMR for at least 72 weeks for patients treated with Scemblix was 96.7% (95% CI, 87.4%–99.2%), reflecting long-term durability of efficacy1.

Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial

Basel, June 6, 2022 — Novartis today announced Tafinlar® (dabrafenib) + Mekinist® (trametinib) significantly improved efficacy in patients ages 1 to 17 years old with BRAF V600 pediatric low-grade glioma (pLGG) requiring first systemic treatment compared to chemotherapy, the current standard-of-care for these patients1. In this study, patients randomized to receive Tafinlar + Mekinist experienced a statistically significant overall response rate (ORR) of 47% (CI: 35-59%) compared to 11% (CI: 3-25%, p

Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study

AbbVie

Viatris

Investors should be able to count on recurring income with these stocks.

3 Great Dividend Stocks to Buy in June

NEW YORK--(BUSINESS WIRE)-- #AG--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) on behalf of Novartis stockholders. Our investigation concerns whether Novartis has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On May 5, 2022, Novartis “announced a temporary, voluntary suspension of pr

NOVARTIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Novartis AG on Behalf of Novartis Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Novartis investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Novartis AG (NVS) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) investors concerning the Company's possible violations of federal securities laws. On May 5, 2022, Novartis "announced a temporary, voluntary suspension of production at its radioligand therapy production sites in Ivrea, Italy and Millburn, New Jersey." The production halt was to "address potential quality issues identified in its manufactu

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Novartis AG (NVS) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On May 5, 2022, Novartis "announced a temporary, voluntary suspension of production at its radioligand therapy production sites in Ivrea, Italy and Millburn, New Jersey." The producti

The Law Offices of Frank R. Cruz Announces Investigation of Novartis AG (NVS) on Behalf of Investors

Novartis' (NVS) CAR-T cell therapy Kymriah (tisagenlecleucel) gets an FDA approval for a third indication.

Novartis (NVS) Wins FDA Nod for Label Expansion of Kymriah

Basel, May 28, 2022 — Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. In accordance with the Accelerated Approval Program, continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings1. "We are proud of today's FDA approval of a third indication for Kymriah. We hope this treatment option that has the potential for long-lasting results may help break the unrelenting cycle of treatment for patients with follicular lymphoma,” said Victor Bulto, President, Novartis Innovative Medicines US. “We are on a mission to build on our pioneering work in cell therapy and continue to innovate for patient impact.”

FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma

Goldman Sachs

JPMorgan Chase & Co

Royal Bank of Canada

Verizon

6 Dividend stocks with high yields and low P/E ratios. These 6 dividend stocks have yields greater than 2.5% and P/E ratios lower than 16x with a positive earnings growth forecast for 2023.

6 Dividend Stocks With High Yields and Low P/E Ratios

Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.

Novartis (NVS) Cosentyx Gets Positive CHMP Opinion for JIA

Basel, May 20, 2022 — Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx® (secukinumab), used alone or in combination with methotrexate, in the juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy8.

Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions

Novartis can provide investors with a market-crushing 3.8% dividend yield -- and that isn't all the stock has to offer.

Should You Buy This High-Yielding Big Pharma Stock?

AT&T

If you really decide to sell in May and go away, you may miss out some profits from these undervalued stocks to buy. The post 3 Undervalued Stocks to Buy Before You Sell in May and Go Away appeared first on InvestorPlace.

3 Undervalued Stocks to Buy Before You Sell in May and Go Away

Apple

Despite challenging economic conditions, these companies are unlikely to cut their dividends.

2 Dividend Stocks to Boost Your Passive Income

Basel, May 12, 2022 — Novartis highlights data from across its oncology portfolio at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2022 Hybrid Congress. With nearly 130 abstracts from Novartis-sponsored and investigator-initiated trials accepted, the data showcase research across over 20 compounds in key disease areas, including breast, lung and prostate cancers, leukemia, lymphoma, multiple myeloma and other blood disorders.

Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer

Colgate-Palmolive

Fortis

If you invest in these stocks, it's likely your dividend income will increase over the years.

Got $5,000? Buy and Hold These 3 Dividend Growth Stocks for the Long Haul

The U.S.-listed shares of Novartis AG NVS, -2.53% NOVN, -0.09% fell 2.6% in afternoon trading Thursday, after the Switzerland-based drug maker said it was "temporarily" suspending delivery of its cancer treatments Lutathera and Pluvicto in the U.S., as part of a quality review of its production sites in Millburn, New Jersey and Ivrea, Italy. The delivery suspension follows the company's "temporary, voluntary suspension" of production of its radioligand therapy production sites in New Jersey and Italy, which is due to "an abundance of caution" while it addresses potential quality issues identified in its manufacturing process.

Novartis suspends delivery of cancer treatment as it address potential production issues

Basel, May 4, 2022 — Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in the first-line subgroup of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer. The analysis of patients treated in first-line with Kisqali plus fulvestrant demonstrated a significant OS benefit of nearly 16 months compared to those treated with fulvestrant alone. This updated exploratory OS analysis from the Phase III MONALEESA-3 study will be presented as a late-breaker mini-oral presentation at the 2022 European Society of Medical Oncology (ESMO) Breast Cancer Congress (Abstract #LBA4).

New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients

CEO Vas Narasimhan is seeking acquisitions under $2 billion.

Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?

BeiGene

Novartis AG (NYSE: NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data showed that tislelizumab plus chemotherapy significantly improved overall survival (.

Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial

Molecular Partners AG

Molecular Partners AG (NASDAQ: MOLN) has provided an update regarding the Emergency Use Application (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. The Company says that EUA, in review with the FDA, may require additional clinical data to be.

Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data

Basel, April 27, 2022 — Novartis today announced positive topline results from an interim analysis of the Phase III RATIONALE 306 study, which showed anti-PD-1 immune checkpoint inhibitor tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 expression. Novartis intends to submit these data to regulatory authorities, and will collaborate with BeiGene to present them at an upcoming medical meeting.

Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study

Growing quarterly numbers but below market expectations. Withdrawal from Russia manageable.

Novartis: Comment On Q1 Results

Novartis (NVS) beats on earnings in the first quarter but sales lag expectations. Generic Sandoz business returns to growth.

News for Novartis Stock (NVS)